[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100395464":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":19,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":19,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"4SCAR19 and 4SCAR20\u002F22\u002F70\u002FPSMA\u002F13\u002F79b\u002FGD2","EXPERIMENTAL","Patients who have relapsed and refractory B cell lymphoma (BCL) after chemotherapy will be treated with a combination of 4SCAR gene-engineered T cells.",[13],"Biological: 4SCAR19 and 4SCAR20\u002F22\u002F70\u002FPSMA\u002F13\u002F79b\u002FGD2",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Patients who have relapsed and refractory B cell lymphoma (BCL) after conventional chemotherapy will be treated with multiple 4SCAR gene-engineered T cells",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Lung-Ji Chang, Ph.D","CONTACT","+86 0755 86573763","c@szgimi.org",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":35,"coordinates":36},"Point",[37,38],114.0683,22.54554,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":43,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100395464","phase-1-multi-car-t-cells-targeting-b-cell-lymphomas-100395464",false,"NCT04429438","Multi-CAR-T Cells Targeting B Cell Lymphomas","Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas","Inclusion Criteria:\n\n1. Age older than 6 months.\n2. Primary B cell lymphoma surface expression of CD19 and\u002For CD22\u002FCD70\u002FPSMA\u002F CD13\u002FCD79b\u002FGD2 molecules.\n3. The KPS score over 80 points, and survival time is more than 1 month.\n4. Greater than Hgb 80 g\u002FL.\n5. No contraindications to blood cell collection.\n\nExclusion Criteria:\n\n1. Accompanied with other active diseases, and difficult to assess response after treatment.\n2. Bacterial, fungal, or viral infection, unable to control.\n3. Living with HIV.\n4. Active HBV and HCV infection.\n5. Pregnant and nursing mothers.6. under systemic steroid treatment within a week of the treatment.\n\n7\\. Prior failed CAR-T treatment.","ALL","6 Months","75 Years",{"count":55,"type":56},11,"ESTIMATED","INTERVENTIONAL",[59,60],"PHASE1","PHASE2","This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I\u002FII trial enrolling patients from multiple clinical centers.",[63],"B Cell Lymphoma (BCL)",[65,66,67,68,69,70,71,72,73,74,75],"CAR-T","CD19","CD20","CD22","CD70","PSMA","CD13","CD79b","GD2","PMBCL","CNS-BCL","2026-06-18",{"date":78,"type":79},"2026-06-23","ACTUAL",{"date":81,"type":79},"2026-06-01",{"date":83,"type":56},"2030-12-31",{"name":5,"class":6},1]